BMO Capital reiterates Outperform rating on Eli Lilly stock at $840 price target

Eli Lilly (LLY) received a maintained Outperform rating from BMO Capital, which deemed complete ATTAIN-1 trial data "broadly positive" despite demographic influences on reported efficacy, anticipating a positive market reaction. Concurrently, Eli Lilly plans simultaneous global regulatory submissions for its experimental weight-loss pill, orforforglipron, though its international president expressed caution regarding the U.S. FDA's fast-track process. Analyst sentiment on orforglipron's long-term obesity market potential is mixed, with some firms maintaining high price targets while others, like Berenberg, downgraded the stock citing a perceived market plateau.

Analysis

Eli Lilly (LLY) received continued support from BMO Capital, which maintained its Outperform rating and $840 price target following the release of complete ATTAIN-1 trial data. BMO characterized the results as "broadly positive," attributing lower-than-expected efficacy to demographic factors within the study—specifically, a high proportion of Hispanic (38%) and male (36%) patients who historically show less sensitivity to GLP-1 treatments. This interpretation reframes the data favorably, and coupled with tolerability data showing decreasing gastrointestinal symptoms over time, BMO anticipates a positive market reaction. Separately, the company is advancing its experimental oral weight-loss pill, orforglipron, with plans for simultaneous global regulatory submissions. However, management has expressed caution about using the FDA's new fast-track process due to its uncertainty. This mix of progress and caution is reflected in divergent analyst sentiment; while firms like Cantor Fitzgerald ($825 target) and Bernstein ($1,000 target) remain bullish, Berenberg has downgraded the stock from Buy to Hold, citing concerns of a potential "plateau in the obesity market."

Key Decisions for Investors

• Investors should weigh the positive interpretation of the ATTAIN-1 trial data, where demographic factors rather than drug performance are cited for lower efficacy, against the significant divergence in analyst price targets, which range from $650 to $1,190.
• The downgrade from Berenberg due to a perceived 'plateau in the obesity market' introduces a key risk factor that warrants monitoring overall market growth and competitive dynamics in the weight-loss drug space.
• Closely track Eli Lilly's regulatory submission strategy for its oral drug, orforglipron, as the company's expressed caution regarding the FDA's fast-track process could introduce a variable in its timeline to market.